Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 57.35
(4.08%)
HKD 57.35
(4.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.43 Billion CNY | 1.32% |
| 2022 | 1.68 Billion CNY | 91.38% |
| 2021 | 880.74 Million CNY | 53.12% |
| 2020 | 575.18 Million CNY | 20.59% |
| 2019 | 476.98 Million CNY | 18.92% |
| 2018 | 401.1 Million CNY | 58.83% |
| 2017 | 252.53 Million CNY | -7.06% |
| 2016 | 271.72 Million CNY | 23.15% |
| 2015 | 220.65 Million CNY | 21.23% |
| 2014 | 182.01 Million CNY | 25.55% |
| 2013 | 144.97 Million CNY | 18.59% |
| 2012 | 122.24 Million CNY | 17.36% |
| 2011 | 104.16 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 410.65 Million CNY | -13.76% |
| 2024 Q2 | 413.6 Million CNY | 0.72% |
| 2024 Q3 | 406.46 Million CNY | 6.34% |
| 2023 Q2 | 399.72 Million CNY | 13.1% |
| 2023 FY | 1.7 Billion CNY | 1.32% |
| 2023 Q4 | 476.17 Million CNY | -0.51% |
| 2023 Q3 | 478.59 Million CNY | 19.73% |
| 2023 Q1 | 353.43 Million CNY | -42.18% |
| 2022 Q3 | 421.74 Million CNY | 25.35% |
| 2022 FY | 1.68 Billion CNY | 91.38% |
| 2022 Q4 | 611.23 Million CNY | 44.93% |
| 2022 Q2 | 336.45 Million CNY | 6.41% |
| 2022 Q1 | 316.17 Million CNY | -1.12% |
| 2021 Q1 | 179.41 Million CNY | 1.67% |
| 2021 Q4 | 319.74 Million CNY | 39.45% |
| 2021 FY | 880.74 Million CNY | 53.12% |
| 2021 Q3 | 229.28 Million CNY | 50.56% |
| 2021 Q2 | 152.28 Million CNY | -15.12% |
| 2020 Q1 | 117 Million CNY | 10.31% |
| 2020 Q2 | 123.8 Million CNY | 5.82% |
| 2020 FY | 575.18 Million CNY | 20.59% |
| 2020 Q3 | 157.9 Million CNY | 27.54% |
| 2020 Q4 | 176.47 Million CNY | 11.76% |
| 2019 Q3 | 129.72 Million CNY | -2.35% |
| 2019 Q1 | 108.36 Million CNY | -3.25% |
| 2019 Q2 | 132.83 Million CNY | 22.59% |
| 2019 FY | 476.98 Million CNY | 18.92% |
| 2019 Q4 | 106.06 Million CNY | -18.23% |
| 2018 Q1 | 71.7 Million CNY | -2.63% |
| 2018 FY | 401.1 Million CNY | 58.83% |
| 2018 Q4 | 111.99 Million CNY | -13.5% |
| 2018 Q3 | 129.46 Million CNY | 47.23% |
| 2018 Q2 | 87.93 Million CNY | 22.63% |
| 2017 Q2 | 38.53 Million CNY | -43.37% |
| 2017 FY | 252.53 Million CNY | -7.06% |
| 2017 Q4 | 73.64 Million CNY | 1.82% |
| 2017 Q3 | 72.32 Million CNY | 87.69% |
| 2017 Q1 | 68.03 Million CNY | -29.04% |
| 2016 Q1 | 46.94 Million CNY | -20.62% |
| 2016 FY | 271.72 Million CNY | 23.15% |
| 2016 Q4 | 95.88 Million CNY | 57.04% |
| 2016 Q3 | 61.06 Million CNY | -10.0% |
| 2016 Q2 | 67.84 Million CNY | 44.53% |
| 2015 Q3 | 50.5 Million CNY | 0.0% |
| 2015 Q4 | 59.13 Million CNY | 17.09% |
| 2015 FY | 220.65 Million CNY | 21.23% |
| 2014 FY | 182.01 Million CNY | 25.55% |
| 2013 FY | 144.97 Million CNY | 18.59% |
| 2012 FY | 122.24 Million CNY | 17.36% |
| 2011 FY | 104.16 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | -340.732% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | -93.789% |